These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
357 related articles for article (PubMed ID: 32516359)
21. Sulbactam-Durlobactam, A Novel Drug for the Treatment of Multidrug Resistant Velmurugan H; Venkatesan S; Meles HN; Neelambaram K; Thangaraju P Infect Disord Drug Targets; 2024; 24(6):e220124225835. PubMed ID: 38258766 [TBL] [Abstract][Full Text] [Related]
22. Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections. Watkins RR; Bonomo RA Clin Infect Dis; 2023 May; 76(Suppl 2):S163-S165. PubMed ID: 37125465 [TBL] [Abstract][Full Text] [Related]
23. In vitro activity of apramycin (EBL-1003) in combination with colistin, meropenem, minocycline or sulbactam against XDR/PDR Acinetobacter baumannii isolates from Greece. Galani I; Souli M; Katsala D; Karaiskos I; Giamarellou H; Antoniadou A J Antimicrob Chemother; 2024 May; 79(5):1101-1108. PubMed ID: 38501368 [TBL] [Abstract][Full Text] [Related]
25. Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant August B; Matlob A; Kale-Pradhan PB Ann Pharmacother; 2024 Jul; 58(7):735-741. PubMed ID: 37817550 [TBL] [Abstract][Full Text] [Related]
26. Characterization of Miller AA; Moussa SH; McLeod SM Antimicrob Agents Chemother; 2024 May; 68(5):e0169823. PubMed ID: 38567976 [No Abstract] [Full Text] [Related]
28. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. Sheng WH; Wang JT; Li SY; Lin YC; Cheng A; Chen YC; Chang SC Diagn Microbiol Infect Dis; 2011 Jul; 70(3):380-6. PubMed ID: 21558048 [TBL] [Abstract][Full Text] [Related]
29. Efficacy of sulbactam and its combination with imipenem, colistin and tigecycline in an experimental model of carbapenem-resistant Acinetobacter baumannii sepsis. Dinc G; Demiraslan H; Elmali F; Ahmed SS; Metan G; Alp E; Doganay M Chemotherapy; 2013; 59(5):325-9. PubMed ID: 24525528 [TBL] [Abstract][Full Text] [Related]
30. The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex. O'Donnell JP; Bhavnani SM Clin Infect Dis; 2023 May; 76(Suppl 2):S202-S209. PubMed ID: 37125469 [TBL] [Abstract][Full Text] [Related]
31. In vitro activities of colistin and ampicillin/sulbactam against Acinetobacter baumannii. Punpanich W; Munsrichoom A; Srisarang S; Treeratweeraphong V J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S95-100. PubMed ID: 22043760 [TBL] [Abstract][Full Text] [Related]
32. Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species. Papp-Wallace KM; McLeod SM; Miller AA Clin Infect Dis; 2023 May; 76(Suppl 2):S194-S201. PubMed ID: 37125470 [TBL] [Abstract][Full Text] [Related]
33. [Evaluation of Colistin-Ampicillin/Sulbactam Combination Efficacy in Imipenem-Resistant Acinetobacter baumannii Strains]. Cıkman A; Ceylan MR; Parlak M; Karahocagil MK; Berktaş M Mikrobiyol Bul; 2013 Jan; 47(1):147-51. PubMed ID: 23390912 [TBL] [Abstract][Full Text] [Related]
34. Difference in imipenem, meropenem, sulbactam, and colistin nonsusceptibility trends among three phenotypically undifferentiated Acinetobacter baumannii complex in a medical center in Taiwan, 1997-2007. Liang-Yu C; Kuo SC; Liu CY; Luo BS; Huang LJ; Lee YT; Chen CP; Chen TL; Fung CP J Microbiol Immunol Infect; 2011 Oct; 44(5):358-63. PubMed ID: 21524973 [TBL] [Abstract][Full Text] [Related]
38. Principe L; Di Bella S; Conti J; Perilli M; Piccirilli A; Mussini C; Decorti G Antibiotics (Basel); 2022 Dec; 11(12):. PubMed ID: 36551450 [TBL] [Abstract][Full Text] [Related]
39. Minocycline Alone and in Combination with Polymyxin B, Meropenem, and Sulbactam against Carbapenem-Susceptible and -Resistant Acinetobacter baumannii in an Beganovic M; Daffinee KE; Luther MK; LaPlante KL Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318006 [No Abstract] [Full Text] [Related]
40. Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of Moussa SH; Shapiro AB; McLeod SM; Iyer R; Carter NM; Tsai Y-K; Siu LK; Miller AA Antimicrob Agents Chemother; 2023 Nov; 67(11):e0066523. PubMed ID: 37843305 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]